Back to Search
Start Over
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2022 Feb; Vol. 63 (2), pp. 326-334. Date of Electronic Publication: 2021 Oct 20. - Publication Year :
- 2022
-
Abstract
- Patients with diffuse large B-cell lymphoma (DLBCL) treated with the R-CHOP regime receive a high cumulative dose of prednisone. We used computer tomography-ascertained Hounsfield units (HU) as a surrogate parameter for bone mineral density (BMD) in three different locations of the L3 vertebral body at baseline and post-treatment. HU were measured in 50 patients with DLBCL of the previously published FLYER-trial which compared four cycles of R-CHOP + 2 × rituximab infusion to six cycles of R-CHOP in young, favorable DLBCL patients. In total, median loss was 26.8 HU in all patients over time. The median HU loss was significantly lower in the four cycles arm (21.3 HU vs. 41.3 HU, p = 0.023). In conclusion, young patients with DLBCL receiving R-CHOP have significant HU/BMD loss under treatment with R-CHOP. Patients receiving four cycles of R-CHOP had less HU/BMD loss than patients receiving six cycles.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols adverse effects
Cyclophosphamide therapeutic use
Doxorubicin therapeutic use
Humans
Prednisone adverse effects
Rituximab
Vincristine adverse effects
Bone Density
Lymphoma, Large B-Cell, Diffuse diagnosis
Lymphoma, Large B-Cell, Diffuse drug therapy
Lymphoma, Large B-Cell, Diffuse etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 63
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 34668817
- Full Text :
- https://doi.org/10.1080/10428194.2021.1975193